Cellectis S.A. (ALCLS.PA)
EUR 1.45
(4.01%)
EUR 1.45
(4.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -101.05 Million USD | -2.4% |
| 2022 | -98.68 Million USD | -14.38% |
| 2021 | -86.28 Million USD | -18.89% |
| 2020 | -72.57 Million USD | 19.98% |
| 2019 | -90.68 Million USD | -15.24% |
| 2018 | -78.69 Million USD | 20.81% |
| 2017 | -99.36 Million USD | -55.46% |
| 2016 | -63.91 Million USD | -184.58% |
| 2015 | -22.46 Million USD | -92455.28% |
| 2014 | 24.32 Thousand USD | 100.03% |
| 2013 | -84.27 Million USD | -186.15% |
| 2012 | -29.45 Million USD | 4.67% |
| 2011 | -30.89 Million USD | -188.12% |
| 2010 | -10.72 Million USD | -94.3% |
| 2009 | -5.51 Million USD | -3323.15% |
| 2008 | 171.22 Thousand USD | 103.93% |
| 2007 | -4.35 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 5.64 Million USD | 113.17% |
| 2024 Q2 | -25.27 Million USD | -547.81% |
| 2023 Q3 | -17.48 Million USD | -64.18% |
| 2023 FY | -101.05 Million USD | -2.4% |
| 2023 Q4 | -42.86 Million USD | -145.18% |
| 2023 Q1 | -30.07 Million USD | -17.01% |
| 2023 Q2 | -10.64 Million USD | 64.59% |
| 2022 Q4 | -25.7 Million USD | -4.16% |
| 2022 Q1 | -31.42 Million USD | 22.62% |
| 2022 FY | -98.68 Million USD | -14.38% |
| 2022 Q2 | -4.32 Million USD | 86.24% |
| 2022 Q3 | -24.67 Million USD | -470.65% |
| 2021 Q3 | -37.41 Million USD | 6.28% |
| 2021 Q2 | -39.91 Million USD | -236.36% |
| 2021 Q4 | -40.6 Million USD | -8.54% |
| 2021 FY | -86.28 Million USD | -18.89% |
| 2021 Q1 | -11.86 Million USD | 70.77% |
| 2020 FY | -72.57 Million USD | 19.98% |
| 2020 Q1 | 20.08 Million USD | 153.97% |
| 2020 Q2 | -32.26 Million USD | -260.66% |
| 2020 Q3 | -30.29 Million USD | 6.09% |
| 2020 Q4 | -40.6 Million USD | -34.03% |
| 2019 Q2 | -33.44 Million USD | -119.35% |
| 2019 Q3 | -15.99 Million USD | 52.17% |
| 2019 FY | -90.68 Million USD | -15.24% |
| 2019 Q1 | -15.24 Million USD | 33.92% |
| 2019 Q4 | -37.21 Million USD | -132.58% |
| 2018 FY | -78.69 Million USD | 20.81% |
| 2018 Q4 | -23.07 Million USD | -1.18% |
| 2018 Q3 | -22.8 Million USD | -214.29% |
| 2018 Q2 | -7.25 Million USD | 71.48% |
| 2018 Q1 | -25.43 Million USD | 6.38% |
| 2017 Q3 | -26.15 Million USD | 5.07% |
| 2017 Q4 | -27.17 Million USD | -3.89% |
| 2017 FY | -99.36 Million USD | -55.46% |
| 2017 Q2 | -27.55 Million USD | -38.86% |
| 2017 Q1 | -19.84 Million USD | -51.32% |
| 2016 Q2 | -6.95 Million USD | 79.16% |
| 2016 Q4 | -13.11 Million USD | 7.17% |
| 2016 Q3 | -14.12 Million USD | -103.01% |
| 2016 FY | -63.91 Million USD | -184.58% |
| 2016 Q1 | -33.39 Million USD | -436.3% |
| 2015 Q2 | -24.86 Million USD | -473.54% |
| 2015 FY | -22.46 Million USD | -92455.28% |
| 2015 Q1 | 6.65 Million USD | 48.83% |
| 2015 Q4 | 9.92 Million USD | 169.12% |
| 2015 Q3 | -14.36 Million USD | 42.22% |
| 2014 Q1 | -3.13 Million USD | 58.88% |
| 2014 FY | 24.32 Thousand USD | 100.03% |
| 2014 Q4 | 4.47 Million USD | -4.09% |
| 2014 Q3 | 4.66 Million USD | 249.81% |
| 2014 Q2 | -3.11 Million USD | 0.64% |
| 2013 Q3 | -7.48 Million USD | 21.95% |
| 2013 Q4 | -7.61 Million USD | -1.75% |
| 2013 FY | -84.27 Million USD | -186.15% |
| 2013 Q1 | -9.45 Million USD | -80.43% |
| 2013 Q2 | -9.59 Million USD | -1.46% |
| 2012 Q4 | -5.24 Million USD | 22.95% |
| 2012 FY | -29.45 Million USD | 4.67% |
| 2012 Q3 | -6.8 Million USD | 0.0% |
| 2011 FY | -30.89 Million USD | -188.12% |
| 2010 FY | -10.72 Million USD | -94.3% |
| 2009 FY | -5.51 Million USD | -3323.15% |
| 2008 FY | 171.22 Thousand USD | 103.93% |
| 2007 FY | -4.35 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -2772.626% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 31.597% |
| Adocia SA | -21.16 Million EUR | -377.549% |
| Aelis Farma SA | -5.07 Million EUR | -1890.134% |
| Biophytis S.A. | -17.02 Million EUR | -493.557% |
| Advicenne S.A. | -7.03 Million EUR | -1337.335% |
| genOway Société anonyme | 1.56 Million EUR | 6546.837% |
| IntegraGen SA | -171.39 Thousand EUR | -58861.254% |
| Medesis Pharma S.A. | -3.95 Million EUR | -2452.323% |
| Neovacs S.A. | -8.74 Million EUR | -1055.825% |
| NFL Biosciences SA | -3.74 Million EUR | -2598.162% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 127749.711% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -3087.029% |
| Sensorion SA | -22.06 Million EUR | -358.039% |
| Theranexus Société Anonyme | -6.82 Million EUR | -1380.078% |
| TME Pharma N.V. | -6.73 Million EUR | -1400.282% |
| Valbiotis SA | -7.36 Million EUR | -1271.593% |
| TheraVet SA | -1.57 Million EUR | -6333.982% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -396.751% |
| DBV Technologies S.A. | -67.26 Million EUR | -50.23% |
| Genfit S.A. | -28.89 Million EUR | -249.758% |
| GeNeuro SA | -14.75 Million EUR | -584.821% |
| Innate Pharma S.A. | -7.57 Million EUR | -1234.993% |
| Inventiva S.A. | -110.42 Million EUR | 8.483% |
| MaaT Pharma SA | -19.71 Million EUR | -412.548% |
| MedinCell S.A. | -25.03 Million EUR | -303.622% |
| Nanobiotix S.A. | -39.7 Million EUR | -154.557% |
| OSE Immunotherapeutics SA | -23 Million EUR | -339.33% |
| Poxel S.A. | -35.09 Million EUR | -187.999% |
| GenSight Biologics S.A. | -26.22 Million EUR | -285.427% |
| Transgene SA | -22.32 Million EUR | -352.611% |
| Valneva SE | -101.42 Million EUR | 0.365% |